Promisia Healthcare Limited Issues 4 Billion Warrants

Highlights:

• Significant Capital Issuance: Promisia Healthcare Limited issued 4 billion warrants, significantly expanding its capital structure.
• Non-Cash Consideration: The warrants were issued without cash consideration, linked to the share purchase plan and placements offer from July 2024.
• Exercise Terms: Warrants can be exercised before March 24, 2027, at an exercise price of $0.002, with issued shares ranking equally with existing fully paid ordinary shares.

Capital Change Details Announced

Promisia Healthcare Limited (NZX: PHL) has announced a significant capital change, issuing 4 billion warrants. These warrants, identified by the ISIN NZPHLE0002S3, have been issued in New Zealand dollars (NZD) as part of the company's strategic financial maneuvers.

No Cash Consideration Involved

Unlike traditional financial product issuance, these warrants were issued without cash consideration. Instead, the non-cash consideration involved participants engaging in the share purchase plan and placements offer announced on July 2, 2024. For every new share allotted under that offer, participants received one warrant. This approach aligns with Promisia Healthcare Limited's innovative strategy to enhance shareholder value without immediate cash outflows.

Key Terms and Future Prospects

The issued warrants carry several key terms:

• Exercise Period: Warrants can be exercised at any time before the expiry date of March 24, 2027.
• Exercise Price: Each warrant can be converted to ordinary shares at an exercise price of $0.002.
• Ranking: Upon exercise, the ordinary shares issued will rank equally with all other fully paid ordinary shares on issue in PHL.

The issuance is authorized under Listing Rule 4.2.1, supported by Board resolutions. The total number of financial products of this class now stands at 4 billion, marking a significant expansion in Promisia Healthcare Limited's capital structure.

Strategic Financial Move

This issuance of warrants aligns with the company's ongoing efforts to settle its share purchase plan and placements offer, providing a structured approach to capital management and growth. The decision to issue these warrants without cash consideration highlights Promisia Healthcare Limited's innovative approach to rewarding and engaging its shareholders while ensuring the company's financial stability and future growth potential.

As Promisia Healthcare Limited continues to navigate the complex healthcare market, this strategic move positions the company for sustained growth and enhanced shareholder value, reinforcing its commitment to innovative financial solutions and robust market performance.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com